https://www.pharmaradar360.com/article/669695d568b39724PharmaRadar360en2026-04-17T10:19:54.000ZLa AEMPS informa de retrasos en el restablecimiento del suministro de Tenormin 0,5 mg/ml solución inyectablehttps://www.pharmaradar360.com/article/d8c4b40e3578f832PharmaRadar360en2026-04-17T09:54:25.000ZΚύρια σημεία συνεδρίασης της Επιτροπής Αξιολόγησης Κινδύνου Φαρμακοεπαγρύπνησης (PRAC), 7 – 10 Απριλίου 2026https://www.pharmaradar360.com/article/fb4b9af133f7ccd2PharmaRadar360en2026-04-17T09:37:00.000ZPromotional material: National AI Commission: Ask Me Anythinghttps://www.pharmaradar360.com/article/a19ff0bb7ec5a11cPharmaRadar360en2026-04-17T09:11:51.000ZAspen Australia participates in the 2026 APP Conferencehttps://www.pharmaradar360.com/article/83d3c5118f9af212PharmaRadar360en2026-04-17T07:44:47.000ZDispositifs médicaux et dispositifs médicaux de diagnostic in vitro : un arbre décisionnel pour aider les acteurs concernés par l’article 10bis des règlements européenshttps://www.pharmaradar360.com/article/2294f21f07d72e1cPharmaRadar360en2026-04-17T07:41:34.000Zเตรียมตัวพบกับ! งานบ้านและสวนแฟร์ ขอนแก่น บ้านเฮามักม่วน 2026https://www.pharmaradar360.com/article/206551bd14516dc7PharmaRadar360en2026-04-17T07:28:17.000Zอมรินทร์เปิดเวทีค้นหา “นักพัฒนาชุมชนพอเพียงรุ่นใหม่”https://www.pharmaradar360.com/article/823ce2006bfd78eePharmaRadar360en2026-04-17T07:20:10.000ZΑνάκληση του συμπληρώματος διατροφής MemoVigor2, δισκία, με αρ. παρτίδας Ι015 και ημερομηνία λήξης 02/2027https://www.pharmaradar360.com/article/a6a1b0a875b85061PharmaRadar360en2026-04-17T06:00:00.000ZOtsuka Pharmaceutical Receives Judges' Special Award at MAFF's 10th Shokuiku Activity Awards "MoguMogu Town" App Recognized for Promoting Food and Nutrition Educationhttps://www.pharmaradar360.com/article/a575e8ea4849f5e4PharmaRadar360en2026-04-17T00:00:00.000ZSanten China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Products in the Chinese Mainlandhttps://www.pharmaradar360.com/article/764269c836e855a5PharmaRadar360en2026-04-17T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/42de297ba1def77bPharmaRadar360en2026-04-17T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/ee36e7521659db5dPharmaRadar360en2026-04-17T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/d6f0c471d803f9edPharmaRadar360en2026-04-17T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/37b6cb84d222f020PharmaRadar360en2026-04-17T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/49a858db4ca096faPharmaRadar360en2026-04-17T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/6f106eb05783cda7PharmaRadar360en2026-04-17T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/8d5e69e551da9d1cPharmaRadar360en2026-04-17T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/1c791584877e4df8PharmaRadar360en2026-04-17T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/eb97d02acc1970bfPharmaRadar360en2026-04-17T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/83c9c968a95cc378PharmaRadar360en2026-04-17T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/58d08a610a5e9c45PharmaRadar360en2026-04-17T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/bb0589414f518385PharmaRadar360en2026-04-17T00:00:00.000Z6203https://www.pharmaradar360.com/article/274e5c403a5a167bPharmaRadar360en2026-04-17T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/d494831537d6d5eePharmaRadar360en2026-04-16T16:29:00.000ZOral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability Without Reactive Metabolites or Metabolic/Safety Liability In Vitro or In Vivohttps://www.pharmaradar360.com/article/7fff93584470c64bPharmaRadar360en2026-04-16T16:00:00.000ZHHS budget hearing not so much about budgethttps://www.pharmaradar360.com/article/c9234583805ba8e3PharmaRadar360en2026-04-16T13:34:30.000ZStatutory guidance: MHRA feeshttps://www.pharmaradar360.com/article/5ed9e5f525ba38d7PharmaRadar360en2026-04-16T13:00:00.000ZCSPC’s SYS-6051 cleared for clinic in China for solid tumorshttps://www.pharmaradar360.com/article/81d92746e94c6162PharmaRadar360en2026-04-16T13:00:00.000ZChina’s NMPA accepts Mabwell’s IND application for 6MW5311https://www.pharmaradar360.com/article/4b619811c8e94f8cPharmaRadar360en2026-04-16T12:46:36.000ZTulipe et le Snitem signent un partenariat pour renforcer la mobilisation des industries de santé dans l’aide médicale humanitairehttps://www.pharmaradar360.com/article/074307b21ae06ff6PharmaRadar360en2026-04-16T11:13:24.000ZClinical trials for medicines: guidance on compliance with ICH E6 good clinical practice (GCP) in the United Kingdomhttps://www.pharmaradar360.com/article/b88868728d7e8b22PharmaRadar360en2026-04-16T11:13:16.000ZClinical trials for medicines: guidance on quality and risk proportionalityhttps://www.pharmaradar360.com/article/450d8618e024178cPharmaRadar360en2026-04-16T11:00:00.000ZTiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Functionhttps://www.pharmaradar360.com/article/3273754290d33e5aPharmaRadar360en2026-04-16T10:45:00.000ZACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic healthhttps://www.pharmaradar360.com/article/ed7de102a9c63724PharmaRadar360en2026-04-16T09:37:10.000ZGuidance: Clinical trials for medicines: roles and responsibilitieshttps://www.pharmaradar360.com/article/18d42bac1298dcd5PharmaRadar360en2026-04-16T07:53:00.000ZΔήλωση Αποθεμάτων Φαρμάκων Ανθρώπινης Χρήσηςhttps://www.pharmaradar360.com/article/503c871cc1064f1cPharmaRadar360en2026-04-16T00:00:00.000ZEducational Initiatives for the Next Generation - Implementing Health Education for Elementary School Students and SDGs Education for Junior and Senior High School Students -https://www.pharmaradar360.com/article/26a07e73cc6109f3PharmaRadar360en2026-04-15T16:23:07.000ZTransparency data: MHRA annual accountability review minuteshttps://www.pharmaradar360.com/article/b18a0be282fe3028PharmaRadar360en2026-04-15T16:00:00.000ZFlow of Trump EOs slowing way downhttps://www.pharmaradar360.com/article/fe464bfc1b8e59cfPharmaRadar360en2026-04-15T14:47:07.000ZRecherche & industrie : le rêve d’une France souveraine, à l’épreuve des choixhttps://www.pharmaradar360.com/article/1a4e7d181c54aea3PharmaRadar360en2026-04-15T14:22:17.000ZGuillermo’s Story: Lessons from Patients’ Lives